JPS6340166B2 - - Google Patents
Info
- Publication number
- JPS6340166B2 JPS6340166B2 JP9170380A JP9170380A JPS6340166B2 JP S6340166 B2 JPS6340166 B2 JP S6340166B2 JP 9170380 A JP9170380 A JP 9170380A JP 9170380 A JP9170380 A JP 9170380A JP S6340166 B2 JPS6340166 B2 JP S6340166B2
- Authority
- JP
- Japan
- Prior art keywords
- injection
- cyclodextrin
- benzyl alcohol
- distilled water
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 42
- 239000007924 injection Substances 0.000 claims description 42
- 238000002347 injection Methods 0.000 claims description 42
- 229920000858 Cyclodextrin Polymers 0.000 claims description 16
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 14
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 5
- 229940124641 pain reliever Drugs 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000012153 distilled water Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 206010018910 Haemolysis Diseases 0.000 description 10
- 230000008588 hemolysis Effects 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 7
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000003708 ampul Substances 0.000 description 6
- 229960002462 glycopyrronium bromide Drugs 0.000 description 6
- 230000002949 hemolytic effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 4
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 4
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 3
- 239000011747 thiamine hydrochloride Substances 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940067107 phenylethyl alcohol Drugs 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 1
- -1 and if necessary Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9170380A JPS5718607A (en) | 1980-07-07 | 1980-07-07 | Injection preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9170380A JPS5718607A (en) | 1980-07-07 | 1980-07-07 | Injection preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5718607A JPS5718607A (en) | 1982-01-30 |
| JPS6340166B2 true JPS6340166B2 (zh) | 1988-08-10 |
Family
ID=14033872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9170380A Granted JPS5718607A (en) | 1980-07-07 | 1980-07-07 | Injection preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5718607A (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| AU2004226323A1 (en) * | 2003-03-26 | 2004-10-14 | Becton, Dickinson And Company | Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection |
-
1980
- 1980-07-07 JP JP9170380A patent/JPS5718607A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5718607A (en) | 1982-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3040678B2 (ja) | 高濃度免疫グロブリン製剤及びその製造方法 | |
| AT402259B (de) | Verfahren zur herstellung eines stabilen pharmazeutischen präparats mit einem gehalt an granulozytkolonie stimulierendem faktor | |
| KR100505772B1 (ko) | 개선된정맥투여용농축주사액및주입액 | |
| O’Reilly et al. | Studies on the coumarin anticoagulant drugs: A comparison of the pharmacodynamics of dicumarol and warfarin in man | |
| DE69432179T3 (de) | Eine formulierung des gerinnungsfaktors viii | |
| DE69827357T2 (de) | Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung | |
| LT3806B (en) | Hyaluronic acid associates, composition containing them, process for preparing the composition, process for preparing zinc hyaluronate aqueous solution | |
| EP0100419A2 (de) | Wässrige Lösung zum Suspendieren und Lagern von Zellen, insbesondere Erythrozyten | |
| DE2827027C3 (de) | Gefriergetrocknetes natives Γ-globulin-Präparat zur intravenösen Verabreichung | |
| JPH05503940A (ja) | 新規インスリン組成物 | |
| DE69008513T2 (de) | Pharmazeutische formulierung von plasminogenaktivatorproteinen. | |
| US5314909A (en) | Use of non-steroidal antiiflammatory agents in macular degeneration | |
| DE2917899A1 (de) | Lyophilisierte urokinasezubereitung zu injektionszwecken und verfahren zu ihrer herstellung | |
| KR19980033113A (ko) | 국소 마취제 수용액, 국소 마취제의 용해도를 개선시키는 방법, 신경독성이 감소된 국소 마취제 및 국소 마취제의 신경 독성을 감소시키는 방법 | |
| US5276044A (en) | Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions | |
| CH641044A5 (de) | Prostacyclin und prostacyclin-derivate enthaltende pharmazeutische zubereitung und verfahren zu ihrer herstellung. | |
| US4289783A (en) | Etomidate-containing compositions | |
| DE1442134C3 (de) | In vivo antikoagulierend wirkendes und defibrinierendes Enzym | |
| JPS6340166B2 (zh) | ||
| DE602004006024T2 (de) | Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose | |
| DE60022759T2 (de) | Erythropoietin formulierungen des mehrfachdosis-typs | |
| JPS5920647B2 (ja) | 注射剤 | |
| JPH02193931A (ja) | 角膜疾患治療用点眼剤 | |
| DE2409650C3 (de) | Verwendung wäßriger Lösung von menschlichem Serum-Haptoglobin bei der Bekämpfung von hämolytischen Nierenstörungen | |
| EP0123142B1 (de) | Verfahren zur Stabilisierung von Hämatin |